We use cookies to ensure we give you
the best possible experience on our website.
There is considerable risk in drug trials. Drug developers don't always know if the patient is complying with the therapy, the causation of adverse events or which subgroups are most benefiting from a drug.
Current Health can change that by providing drug developers with unparalleled phenotypical data throughout a trial. We deliver continuous, wireless vital signs from our wearable, a complete picture of individual health through our seamless integrations, and ePROs through our patient app.
When a trial participant returns home, it’s difficult for a researcher to know if the protocol is being followed. Current Health adds transparency, helping the researcher objectively track a patient’s health at home—24/7. We provide both visibility into physical health, through our wearable and seamless integrations, and subjective health, through ePROs via our app. The outcome is more accurate, lower risk research and greater context for pharmaceutical companies.
A large volume of data doesn’t need to impede patient-level research. We’re taking steps to de-silo and structure large-scale data to deliver personalized insights. This allows us to identify subgroups who most benefit and are most at risk to interventions—ultimately resulting in drugs tailored to the individual level.
Once a drug is approved, our technology can enable proactive prescription. Our platform will be able to support the progress and tracking of new drugs by deepening the understanding of patient-level health and allow more appropriate delivery of medications at the right time.
The CRO enrols a new participant into a clinical trial for a new oncology drug. They are sent home with Current Health.
The CRO enrols a new participant into a clinical trial for a new oncology drug. They are sent home with Current Health.
Current Health monitors the patient through the wearable device and a wirelessly integrated spirometer and scale. The data is automatically transmitted straight to the CRO's EDC vendor.
Current Health monitors the patient through the wearable device and a wirelessly integrated spirometer and scale. The data is automatically transmitted straight to the CRO's EDC vendor.
The research team can correlate adverse events with physiological data to better determine causation, as well as identify sub-groups who might derive even more significant benefit from their new drug.
The research team can correlate adverse events with physiological data to better determine causation, as well as identify sub-groups who might derive even more significant benefit from their new drug.
The CRO enrols a new participant into a clinical trial for a new oncology drug. They are sent home with Current Health.
Current Health monitors the patient through the wearable device and a wirelessly integrated spirometer and scale. The data is automatically transmitted straight to the CRO's EDC vendor.
The research team can correlate adverse events with physiological data to better determine causation, as well as identify sub-groups who might derive even more significant benefit from their new drug.